Scarica l'app Stockscreener
1.16
1.74%
0.01
Precedente Chiudi:
$1.15
Aprire:
$1.16
Volume 24 ore:
21,427
Relative Volume:
0.08
Capitalizzazione di mercato:
$15.94M
Reddito:
$743.00K
Utile/perdita netta:
$-7.63M
Rapporto P/E:
-0.3867
EPS:
-3
Flusso di cassa netto:
-
1 W Prestazione:
+0.00%
1M Prestazione:
-20.88%
6M Prestazione:
-49.57%
1 anno Prestazione:
-40.61%
Intervallo 1D:
$1.15
$1.1827
Intervallo di 1 settimana:
$1.13
$1.2058
Portata 52W:
$1.13
$4.69
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Nome
Can-Fite Biopharma Ltd ADR
Settore
Industria
Telefono
972 3 924 1114
Indirizzo
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Confronta CANF con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
1.15 | 15.94M | 743.00K | -7.63M | 0 | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
497.69 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.36 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.90 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.27 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
246.77 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2017-08-11 | Iniziato | Maxim Group | Buy |
| 2016-10-19 | Ripresa | ROTH Capital | Buy |
| 2016-08-29 | Ripresa | Rodman & Renshaw | Buy |
| 2015-11-30 | Reiterato | H.C. Wainwright | Buy |
| 2015-03-31 | Reiterato | H.C. Wainwright | Buy |
| 2015-03-30 | Downgrade | ROTH Capital | Buy → Neutral |
| 2014-12-29 | Reiterato | ROTH Capital | Buy |
| 2014-11-18 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Can-Fite Biopharma Ltd ADR Borsa (CANF) Ultime notizie
Can Fite Biopharma stock hits 52-week low at $1.14 By Investing.com - Investing.com South Africa
Can Fite Biopharma stock hits 52-week low at $1.14 - Investing.com
Can Fite Biopharma stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa
Can Fite Biopharma stock hits 52-week low at $1.22 - Investing.com
Can-Fite BioPharma announces $3M registered direct offering - Investing.com
Can-Fite’s Surging Stock: Is It Time to Act? - timothysykes.com
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits - GlobeNewswire Inc.
USC Law Launches New Online Certificate in Dispute Resolution - Business Wire
Lenovo Integrates AI and Robotics to Deliver Smarter Retail Solutions - Business Wire
Cronos Group Inc (NASDAQ: CRON) Could Slash -12.75% Soon - Stocks Register
Commercial Metals Co (NYSE: CMC) Could Slash -1.03% Soon - Stocks Register
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Reckitt Benckiser Group PLC (OTC: RBGLY) - Business Wire
Can Fite Biopharma stock hits 52-week low at $1.86 - Investing.com India
Can-Fite secures Australian patent for obesity treatment - Investing.com
Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of WeRide Inc. - Business Wire
Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com
Ratios in Focus: Analyzing Can-Fite Biopharma Ltd ADR (CANF)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel
Wearable Devices Ltd. sets annual meeting for September 26 - Investing.com
Martingale Risk – Philips Shareholders Group Action to be Filed in the Netherlands - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire UK
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
bioAffinity Technologies Inc Stock Price Today | NASDAQ: BIAF Live - Investing.com
NOVONIX to Commence Trading on Nasdaq through Level II ADR Program - Business Wire
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma - Business Wire
4 Penny Stocks On Robinhood To Buy Under $4 Now; Worth The Risk? - Penny Stocks
Can-Fite BioPharma (CANF) Stock Price, News & Analysis - MarketBeat
New Lenovo Research: People are Working More by Not Going to Work, but Worry about Home Tech, Data Security and Personal Costs - Business Wire
Global Metal Casting Market 2020-2024 | Evolving Opportunities with Acast and Alcast Co. | Technavio - Business Wire
10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance
Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha
letgo Raises $100 Million in Series A Funding from Naspers - Business Wire
Ipsen Announces That Its Controlling Shareholder, Mayroy, Sold Approximately 7% of Ipsen’s Share Capital via Private Placement - Business Wire
Can-Fite Biopharma Ltd ADR Azioni (CANF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.36%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):